At pharmacological doses, glucagon increases energy expenditure, leading to interest in utilizing the actions of glucagon for the treatment of obesity [13,[26], [27], [28], [29], [30], [31]]. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.